LILAC – TIMI 76

LILAC-TIMI 76 is a randomized, double, blind placebo-controlled phase 3 trial investigating the efficacy and safety of the factor XI inhibitor abelacimab in~1,900 patients with AF deemed unsuitable for anticoagulation therapy. 

LILAC Design Slide 21NOV2022

LILAC on ClinicalTrials.gov

CONTACT US about LILAC

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close